congressional inquiries, as well as proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products
GLP-s1s have been approved for use in people with type 2 diabetes since 2005-2006 in North American & Europe Weight loss, particularly when rapid, a ffects ovulation, fertility, menstrual bleeding, muscle mass, bone density, mental well-being, and cardiometabolic risk
2010;59(Suppl
Because of that gap, the post says providers assess individual risk and benefit before any decision to resume therapy is made
Patients frequently report nausea, diarrhea, vomiting, constipation, and abdominal pain, particularly when initiating treatment or increasing the dosage
Headaches (moderately worse) GLP-1 related headaches combined with alcohol-induced dehydration headaches create a compounding effect